A Multicenter, Randomized, Single-Masked Comparison of Lucentis™ Monotherapy With Triple Therapy of Reduced Fluence Visudyne-Lucentis-Dexamethasone (V-L-D) in Patients With CNV Secondary to AMD as Second Line Therapy After Lucentis Monotherapy

NCT00457678 Phase 2 WITHDRAWN

The purpose of this study is to demonstrate that Visudyne-Lucentis-dexamethasone (V-L-D) triple therapy will give similar efficacy and safety results as Lucentis monotherapy.

Details

Lead sponsor	Vitreous -Retina- Macula Consultants of New York
Phase	Phase 2
Status	WITHDRAWN
Start date	2007-01
Completion	2007-12-04

Conditions

• Age Related Macular Degeneration

Interventions

• Visudyne
• Lucentis
• Dexamethasone